Evidence map›Paper›PMID 42259600›Full record

ArticleJournal for immunotherapy of cancer2026

CD70-targeted platform for diagnosing and treating multiple myeloma.

Jun Li, Haoyi Yan, Xiaoyan Wang, You Zhang, Ping Chen, Jia Feng, Rui Zhang, Zhan Li, Zixuan Huang, Chuanmian Xu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jun Li *Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Haoyi Yan *Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Xiaoyan Wang *Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
You ZhangDepartment of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ping ChenDepartment of Pharmacy, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Jia FengDepartment of Hematology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Rui ZhangDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Zhan LiDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Zixuan HuangDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Chuanmian XuDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Ning MaDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Xiaohua LinDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Minyi ZhaoDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Wenjing ZhuInstitute of Biomedical Engineering, Shenzhen Bay Lab, Shenzhen, Guangdong, China.
Qiyu PengInstitute of Biomedical Engineering, Shenzhen Bay Lab, Shenzhen, Guangdong, China.
Siwei XieInstitute of Biomedical Engineering, Shenzhen Bay Lab, Shenzhen, Guangdong, China.
Weijun WeiDepartment of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China wwei@shsmu.edu.cn mengjiedong@126.com.ORCID http://orcid.org/0000-0003-3190-2480
Mengjie DongDepartment of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China wwei@shsmu.edu.cn mengjiedong@126.com.ORCID http://orcid.org/0009-0004-9881-4631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD70, overexpressed in multiple myeloma (MM), is a promising target for theranostics. This study developed a CD70-targeted theranostic pair: the immuno-positron emission tomography tracer [

methodsCD70 expression was confirmed in patients with MM samples (positivity rate, 66.7%) and RPMI-8226 xenografts. The nanobody derivative ABDB6 was conjugated to DFO or DOTA and radiolabeled with

results[

conclusionsThe CD70-targeted theranostic pair allows precise imaging and effective radiotherapy in MM models. Low-dose [

Indexed as

CD27 LigandMultiple MyelomaRadiopharmaceuticalsAnimalsCell Line, TumorFemaleHumansLutetiumMaleMiceMice, NudePositron-Emission TomographyRadioisotopesTissue DistributionXenograft Model Antitumor AssaysZirconiumCD27 LigandCD70 protein, humanLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsZirconiumAntibodyBiomarkerMultiple Myeloma

Identifiers

PMID42259600
PMCPMC13250178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.